| Name | Title | Contact Details |
|---|
Emendo biotherapeutics develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials.
DWIHN provides support to children with serious emotional disturbance, people with mental illness, developmental disability and/or substance use disorder.
At Santen, we`re innovating therapies to improve the quality of life for patients worldwide. Our single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a global company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Our clinical development network now spans three continents, with centers in EMEA (Europe, the Middle East and Africa), Japan, and the United States.
InnovoTex Inc. is a mid-stage pharmaceutical company developing the TEX Core portfolio of novel therapeutics capable of targeting multiple solid tumor indications.